Pay in 4 interest-free payments of $6.06 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
When this synthetic peptide is injected into the body, the result could vary from individual to individual
most cardiovascular outcome trials excluded patients with end-stage renal disease (ESRD) or those receiving maintenance dialysis
About the HRS9531-301 Clinical Trial The HRS9531-301 clinical trial was a multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical study (NCT06396429) conducted by Hengrui in China to evaluate the efficacy and safety of HRS9531 injection in adults (18 years of age) with obesity (BMI 28 kg/m2) or overweight (BMI 24 kg/m2) and at least one weight-related comorbidity without diabetes
The mothers and their infants were monitored for up to one year after birth
Quality exists only to the extent that individual manufacturers choose to maintain it, and not all of them choose well
US$ 26.61
US$ 27.12
US$ 20.01
US$ 26.35
US$ 24.63
US$ 26.72
US$ 23.67
US$ 21.51
US$ 19.99
